BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Biotechnology

Healthcare
$61.43 -0.18%

-$0.10 today

Market cap
$11.90B
Beta
0.24
P/E (TTM)
39.4
EPS (TTM)
$1.40
52W Low $49.26High $66.28

Volume 3.07M

Average 2.04M

BMRN EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

BioMarin Pharmaceutical Inc.NASDAQ: BMRN

EBITDA · Q3 FY2026 · quarter ended Sep 2026

EBITDA remains negative

Q3 FY2026 EBITDA was -$82.08B, compared with -$5.26M a year earlier. Trailing-twelve-month EBITDA was -$81.69B. Over 3 fiscal years it compounded at +29.2% a year.

Context

  • EBITDA amounted to 17.8% of revenue in FY2025, down 5.0 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 20 analysts of $818.9M (+42.9%) for the fiscal year ending Dec 2026, a step up from the -11.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$82.08B-37020.7% QoQ
Last fiscal yearDec 2025
$572.94M-11.9% YoY
LTMSep 2026
-$81.69B-10676.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1560968.8%+9274.8%+1570243.7 pp
1 year-11.9%+42.9%+54.9 pp
3-year CAGR+29.2%+49.6%+20.3 pp
5-year CAGR+32.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
572.94M USD
Year-over-year change
-11.9%
4-year CAGR
+86.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How BMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -10676.6% is the lowest of 11, against a peer median of +4.7%.
  • EBITDA amounts to 8.0% of revenue for BMRN, versus a peer median of 30.7%.
BMRN Competitors
EBITDA for BMRN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VRTXVertex Pharmaceuticals IncorporatedLTM Sep 2026$4.86B USD+4.3%+3.1%37.4%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$1.15B USD+773.6%—24.0%
ASNDAscendis Pharma A/SLTM Sep 2026€259.93M EUR+295.2%—21.5%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$173.52M USD-79.4%—17.2%
PHARPharming Group N.V.LTM Mar 2026$39.48M USD+82.4%-1.9%10.7%
TVTXTravere Therapeutics, Inc.LTM Sep 2026-$106.58M USD-372.0%—16.4%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-$473.54M USD-208.3%—49.3%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-$503.35M USD-11.9%—75.2%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026-$611.26M USD+5.0%—85.7%
INSMInsmed IncorporatedLTM Jun 2026-$770.76M USD+17.8%—67.8%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-$81.69B USD-10676.6%+29.2%8.0%
Peer median (excluding BMRN) —+4.7%+0.6%30.7%

Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.85B2.1B2.42B2.85B3.22B
Cost of Revenue470.52M503.02M532.06M580.24M736.83M
Gross Profit1.38B1.59B1.89B2.27B2.48B
Gross Margin74.5%76.0%78.0%79.7%77.1%
Research & Development628.79M649.61M746.77M747.18M921.93M
Selling, General & Admin759.4M823.2M892.4M1.01B1.28B
Operating Expenses1.46B1.43B1.7B1.79B1.95B
Depreciation & Amortization108.04M101.97M104.39M96.43M79.56M
EBITDA47.43M265.36M306.77M650.53M572.94M
EBITDA Margin2.6%12.7%12.7%22.8%17.8%
Operating Income(82.34M)160.97M185.77M484.21M533.48M
Operating Margin-4.5%7.7%7.7%17.0%16.6%
Interest Income10.48M18.03M58.34M74.88M74.9M
Interest Expense15.34M15.97M17.34M12.67M10.9M
Other Income / Expenses6.99M(11.4M)2.79M57.55M(51M)
Income Before Tax(75.35M)149.58M188.56M541.76M482.48M
Pre-Tax Margin-4.1%7.1%7.8%19.0%15.0%
Income Tax Expense(11.27M)8.02M20.92M114.9M133.58M
Net Income(64.08M)141.56M167.65M426.86M348.9M
Net Margin-3.5%6.8%6.9%15.0%10.8%
EPS (Basic)(0.35)0.760.892.251.82
EPS (Diluted)(0.35)0.750.882.211.80
Weighted Avg Shares182.85M185.27M187.83M190.03M191.79M
Weighted Avg Shares (Diluted)182.85M188.96M191.6M196.71M197.39M

BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Intrinsic Alpha fair value

Locked

Current Price

$61.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.